

Fig 5-S5




Figure 5–Figure Supplement 5. Regulation of target gene expression by JAK inhibitor.
The *TP53/FXR2* co-deletion cancer cell line H358 is treated with JAK inhibitor (JAKi) S-Ruxolitinib at the dosage of 0, 0.3, or 1 μM for 4 days. The total mRNA is extracted and subjected for q-RT-PCR assay to determine the expression of FXR1 target genes. Data represent mean ± s.d. from three independent experiments. The mRNA level shown in q-RT-PCR is fold change normalized to GAPDH mRNA level. The mRNA level at 0 μM S-Ruxolitinib treatment is set as 1. * $P < 0.05$, *** $P < 0.001$ (comparing to the 0 μM S-Ruxolitinib treatment sample).